Drug Type Antibody drug conjugate (ADC) |
Synonyms Dual-Warhead Conjugate Based on Fibroblast Growth Factor 2 Dimer Loaded with α-Amanitin and Monomethyl Auristatin E |
Target |
Action antagonists, inhibitors |
Mechanism FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | Poland | 14 Jun 2023 |